title: A patient with multiple myeloma, amyloidosis and light-chain deposition disease in kidneys with a long survival.
abstract: We report a case of a 39-year-old man with lambda-light-chain multiple myeloma, nephrotic syndrome due to lambda-light-chain deposition disease in kidneys and amyloidosis in other tissues. The patient was treated with melphalan and prednisone for 1 year. After that, he was administered interferon-alpha2b (IFN-alpha2b; 3 MU, 3 times a week) as maintenance therapy for 2 years. At present, 5 years and 6 months after the initial diagnosis, the patient receives IFN-alpha2b (3 MU, twice a week) and remains in complete haematological remission.
authors.affiliation: Haematology Unit, Department of Internal Medicine, Ioannina Medical School, Ioannina University, Ioannina, Greece.
authors.forename: L
authors.initials: L
authors.lastname: Christou
authors.forename: E C
authors.initials: EC
authors.lastname: Hatzimichael
authors.forename: F
authors.initials: F
authors.lastname: Sotsiou-Candila
authors.forename: K
authors.initials: K
authors.lastname: Siamopoulos
authors.forename: K L
authors.initials: KL
authors.lastname: Bourantas
mesh_terms: D000328:Adult; D000686:Amyloidosis / Q000150:complications / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000378:metabolism*; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D009404:Nephrotic Syndrome / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D017741:Survivors
chemical_list: D000970:Antineoplastic Agents; D007147:Immunoglobulin Light Chains; D016898:Interferon-alpha; D008558:Melphalan; D011241:Prednisone